1040results about How to "Increased toxicity" patented technology

The invention provides transgenic plants and transformed host cells which express modified cry 3B genes with enhanced toxicity to Coleopteran insects. Also disclosed are methods of making and using these transgenic plants, methods of making recombinant host cells expressing these delta -endotoxins, and methods of killing insects such as Colorado potato beetle (Leptinotarsa decemlineata), southern corn rootworm (Diabrotica undecimpunctata howardi Barber) and western corn rootworm (Diabrotica virgifera virgifera LeConte.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

A fire-barrier system comprises at least one alkali silicate resin composition layer and at least one layer of any of the following: an insulation layer, an intumescent layer, a foam layer, a corrugated layer, a reflective surface layer, and a reinforcing material layer. The fire-barrier system when utilize in association with a substrate such as wood, a polymer, etc. provides enhanced fire resistance performance, thermal barrier, an oxidation barrier, and the like.

Essential-oil compositions comprising Lippia javanica essential oil in combination with one, two, three, four, five, six or more essential oils are provided. The Lippia javanica essential-oil compositions are effective for killing and / or repelling ectoparasites and / or pests, including lice, ticks, mosquitoes, mites, ants and fleas. Methods of using the compositions comprising Lippia javanica essential oil in combination with one, two, three, four, five, six or more essential oils for killing or repelling ectoparasites and / or pests also are provided. Also provided are articles of manufacture and kits that include the Lippia javanica essential-oil compositions.

Therapeutic formulations adapted for positive-pressure application for controlling biological fluid at a desired site in a subject, absorbent articles comprising therapeutic formulations, and anti-infective devices coated with therapeutic formulations, said formulations comprising about 25% to about 99% by weight liquid-crystal forming compound and 0% to about 75% by weight solvent. In addition, methods of using said formulations including methods for controlling biological fluid at a desired site in a subject, methods for controlling blood loss, and methods for facilitating effective closure of a vascular wound or incision site at a desired site in a subject are disclosed, the methods comprising administering particular formulations comprising liquid-crystal forming compounds and solvents that are described herein.

The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac—, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.

Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.

Systems and methods are disclosed for microscale pharmacokinetics. Various organs and their interactions with drug compounds can be simulated in vitro by use of microscale compartments that can be interconnected by microscale channels. Cells or cellular materials associated with the organs can be cultured in such compartments to allow interactions with drug compounds in one or more fluidic flows. Such fluidic systems can include, by way of examples, gastrointestinal flow, blood flow, bile flow, urinary flow, and brain fluid flow. Interactions between fluidic systems can be simulated by a microscale permeable member. In one example, blood-biliary interaction can be simulated by a microscale permeable material having hepatocytes bound to a permeable substrate via a binder.

Systems and methods are disclosed for microscale pharmacokinetics. Various organs and their interactions with drug compounds can be simulated in vitro by use of microscale compartments that can be interconnected by microscale channels. Cells or cellular materials associated with the organs can be cultured in such compartments to allow interactions with drug compounds in one or more fluidic flows. Such fluidic systems can include, by way of examples, gastrointestinal flow, blood flow, bile flow, urinary flow, and brain fluid flow. Interactions between fluidic systems can be simulated by a microscale permeable member. In one example, blood-biliary interaction can be simulated by a microscale permeable material having hepatocytes bound to a permeable substrate via a binder.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

Materials and Methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

The invention relates to an electrolyte formulation comprising a) an ionic liquid which is electrochemically stable over a range of at least 4.5 V, has a viscosity of less than 300 mPa·s at 20° C. and has a conductivity of at least 1 mS / cm at 20° C., and b) an aprotic, dipolar solvent in an amount of 20 to 60% by volume based on the electrolyte formulation, wherein the conductivity of the electrolyte formulation is greater at least by a factor of 2 than the conductivity of the ionic liquid.

Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

The invention discloses a sugarcane fertilizer for preventing and treating soil insects and a production method of the sugarcane fertilizer. The sugarcane fertilizer comprises the following ingredients: inorganic fertilizer, organic fertilizer, reagents, plant growth regulating agents and bonding agents, wherein the inorganic fertilizer accounts for 45 to 92 weight percent of the total weight of the sugarcane fertilizer, the organic fertilizer accounts for 7 to 50 weight percent of the total weight of the sugarcane fertilizer, the reagents account for 0.25 to 3.5 weight percent of the total weight of the sugarcane fertilizer, the plant growth regulating agents account for 0.04 to 0.05 weight percent of the total weight of the sugarcane fertilizer, and the bonding agents account for 0.075 to 3.0 weight percent of the total weight of the sugarcane fertilizer. The reagents are combination of phoxim, chlorpyrifos and imidacloprid or dinotefuran according to a weight ratio of (1-2):1:(0.1-4.5), and the plant growth regulating agents are sodium nitrophenolate. Products of the sugarcane fertilizer fully meet the requirement on the nutrition in the sugarcane growth process, simultaneously, the effects of preventing and treating sugarcane insects such as stem borers, sugarcane turtles and grubs and treating insects such as cotton aphids, longicorns and the like can be realized, the yield and the sugar content are improved, and the production cost is also reduced.

The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

The invention discloses an efficient low-toxicity formaldehyde scavenger containing the following raw material components by weight: 0.5%-5% of hydrazide, 0.1%-5% of a water-soluble ester, 0.5%-10% of a moisture absorbent, 0.1%-0.5% and of a buffer, 0.05%-1% of a surface active agent, 0.02%-0.5% of a preservative and 80%-98% of water. The free hydrazine content in the efficient low-toxicity formaldehyde scavenger product is controlled in the range as low as possible by the manner of fine selection of the hydrazide raw material, control of free hydrazine content, adding of the water-soluble ester, adding of the buffer, and the like, and the efficient low-toxicity formaldehyde scavenger product has better security. The efficient low-toxicity formaldehyde scavenger product is good in formaldehyde removal effect, safe to people and objects, and simple in production process, and can be used for governance of the problem of formaldehyde exceeding the standard in new decorated residence or furniture.

A crosslinkable macromer system and related methods of preparing the system and using the system in the form of a crosslinked matrix between a tissue site and an implant article such as a tissue implant or on the porous surface of a prosthetic device. The macromer system includes two or more polymer-pendent polymerizable groups and one or more multifunctional initiator groups. The polymerizable groups and the initiator group(s), when polymer-pendent, can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility. A macromer system of the invention can be used as an interface between the tissue site and implant article in a manner sufficient to permit tissue growth through the crosslinked matrix and between the tissue site and implant. In a preferred embodiment, polymers with pendent polymerizable groups, for use in the macromer system, are prepared by reacting a polysaccharide polymer with a reactive moiety in an organic, polar solvent such as formamide.

Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

The invention discloses a method for treating landfill leachate, which orderly comprises flocculation precipitation pretreatment, hydrolysis pre-acidification treatment, anaerobic treatment, aerobic treatment comprising shortcut nitrification-denitrification and secondary nitrification-denitrification, membrane separation treatment and oxidation flocculation treatment. The method has the advantages of having higher removal rate of ammonia nitrogen and lower energy consumption, realizing the up-to-standard discharge of leachate concentrated solution, ensuring sound operation of the whole system, greatly lowering the oxidation-reduction potential in the anaerobic reaction, and improving the anaerobic treatment effect, thereby making the landfill leachate fully meet the first-level discharge standard of the Integrated Wastewater Discharge Standard.

The present invention relates to a non-human transgenic mammal which has had an HLA-A24 gene introduced and in which CTLs are induced when stimulated by an HLA-A24-binding antigen, a method of screening therapeutic or preventive agents for tumors or virus infections comprising administering a test substance to said transgenic non-human mammal and assaying and evaluating whether CTLs specific for the test substance are induced, an HLA-A24-binding tumor antigen peptide of PSA origin selected by said screening method, a chimera DNA (DNA construct) useful in the generation of said non-human transgenic mammal, a host cell transformed by said chimera gene and use thereof, and the like.

The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusio proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.

The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceutical compositions comprising a combination of an antisense oligonucleotide compound conjugated with a positively charged polymer (“ON-PCP”) and a negatively charged polymer. Pharmaceutical compositions in accordance with the present invention have demonstrated improved antisense efficiency and reductions in cell toxicity compared to compositions that contain an oligonucleotide compound conjugated with a positively charged polymer.

ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.